Results 91 to 100 of about 31,195 (193)

Tigecycline: Its potential for treatment of brucellosis

open access: yes, 2007
The in vitro efficacy and synergistic activity of tigecycline in comparison with other antimicrobials used in brucellosis, were tested for 16 Brucella melitensis strains by the E-test method.
Arman, Dilek   +7 more
core   +2 more sources

Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia

open access: yesInternational Journal of Infectious Diseases, 2017
The successful use of tigecycline in a 12-month old liver transplant recipient with extensively drug-resistant Acinetobacter baumannii bacteremia is presented.
Jiawei Zeng   +7 more
doaj   +1 more source

Immunomodulatory Effects of Tigecycline in Balb/C Mice

open access: yesActa Pharmaceutica, 2018
Tigecycline is a glycylcycline antibiotic approved by the FDA for the treatment of complicated infections. Despite its effectiveness, the FDA announced a warning of increasing mortality associated with its use. There is, however, no clear explanation for
Elhayek Shada Y.   +4 more
doaj   +1 more source

Risk factors with the development of infection with tigecycline- and carbapenem-resistant Enterobacter cloacae

open access: yes, 2019
Yuansu Jiang,* Xiaojiong Jia,* Yun Xia Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China *These authors contributed equally to this work Background: Tigecycline ...
Jiang Y, Xia Y, Jia X
core  

Susceptibility profiles of nine tigecycline-resistant and one tigecycline-susceptible strain.

open access: yes, 2014
Footnote. KB, Kirby-bauer; BMD, broth microdilution; MIC, minimum inhibitory concentration(test by BMD and E-test method) ; ATCC 25922 quality control strain KB value range from 20–27 cm, MIC range from 0.03–0.25 µg/mL.Susceptibility profiles of nine ...
Xin Hu (38924)   +5 more
core   +1 more source

Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy

open access: yesScientific Reports
Background Tigecycline is widely used to treat a variety of bacterial infections despite concerns regarding increased mortality in severe infections.
Sol Jin   +13 more
doaj   +1 more source

Postantibiotic Effects of Tigecycline, Colistin Sulfate, and Levofloxacin Alone or Tigecycline-Colistin Sulfate and Tigecycline-Levofloxacin Combinations against <i>Acinetobacter baumannii</i>

open access: yes, 2010
<i>Background:</i> Colistin sulfate and levofloxacin, alone and in combination with tigecycline, were investigated for their in vitro activities and postantibiotic effects (PAEs) on6 meropenem-resistant<i> Acinetobacter baumannii</i ...
Berna Özbek   +3 more
core   +1 more source

Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights

open access: yes, 2018
Mohamed M Ibrahim,1 Abdulla M Abuelmatty,2 Gehan H Mohamed,3 Mohsen A Nasr,4 Amal K Hussein,5 Mohy El Deen Ebaed,6 Hatem A Sarhan5 1Department of Clinical Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt; 2Department of Pharmacy, Jahra ...
Sarhan HA   +6 more
core  

The tigecycline resistance mechanisms in Gram-negative bacilli [PDF]

open access: yes
Tigecycline, hailed as a pivotal agent in combating multidrug-resistant bacterial infections, confronts obstacles posed by the emergence of resistance mechanisms in Gram-negative bacilli.
Henan Li, Zhiren Wang
core   +1 more source

Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials

open access: yes, 2017
Hal Tucker, Michele Wible, Ashesh Gandhi, Alvaro QuintanaPfizer Inc, Collegeville, PA, USABackground: Acinetobacter infections, especially multidrug-resistant (MDR) Acinetobacter infections, are a global health problem.
Tucker H, Quintana A, Wible M, Gandhi A
core  

Home - About - Disclaimer - Privacy